Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Price Target at $12.08

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received a consensus rating of “Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $11.79.

A number of equities analysts recently issued reports on TLSI shares. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a report on Tuesday. They issued an “overweight” rating and a $10.00 price target for the company. Northland Securities started coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target for the company. Canaccord Genuity Group dropped their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Roth Mkm assumed coverage on TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Oppenheimer initiated coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price target on the stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently bought and sold shares of TLSI. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences during the third quarter worth about $66,000. Virtu Financial LLC purchased a new stake in TriSalus Life Sciences in the 3rd quarter valued at approximately $92,000. Vestcor Inc acquired a new position in TriSalus Life Sciences during the 3rd quarter worth approximately $108,000. MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $184,000. Finally, Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter valued at approximately $240,000. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Stock Down 1.8 %

Shares of NASDAQ:TLSI opened at $3.81 on Friday. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The stock has a market cap of $116.18 million, a price-to-earnings ratio of -1.53 and a beta of 0.56. The firm’s 50 day moving average price is $4.17 and its 200 day moving average price is $4.98.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.